8N10.F Biosergen AB

Healthcare Biotechnology Frankfurt Exchange
0.0405 EUR
Close of Oct 24, 2026
0.0395 4.34
Market cap
EUR 3.35M
P/E
-
P/B
51.10x
ROE
-323.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 8N10.F undervalued?

Graham number

The Graham number of Biosergen AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biosergen AB fundamental analysis

No fundamental analysis for Biosergen AB yet.

Biosergen AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biosergen AB

Biosergen AB (publ), a biotech company, develops antifungal drugs. Its lead product is BSG005, an antifungal drug candidate for the treatment of invasive fungal infections in immunocompromised patients, including AIDS, cancer, and transplant recipients. The company was founded in 2004 and is based in Solna, Sweden.

Full company profile